Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
- Written by PR Newswire
Colorectal impairment reversed in a preclinical model of Parkinson's Disease
ATH434 presents a novel mechanism of action for the treatment of neurodegenerative diseases
 |
MELBOURNE, Australia, Nov. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing...
